BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGuangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stagepharmaceutical company, today announced that dosing has begun in Phase 1clinical study to evaluate the pharmacokinetics, safety, and preliminaryanti-tumor activity of BAT6026 ,a highly differentiated monoclo...
Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177) , a commercial-stage pharmaceuticalcompany, today announced that dosing has begun in Phase 1 clinical study to evaluatethe pharmacokinetics, safety, and preliminary anti-tumor activity of BAT6021, amonoclonal antibody with enh...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in Phase I clinical study to compare thepharmacokinetics and safety of BAT6026, an agonist monoclonal antibodytargeting OX40 in cancer patient vo...